What is Alkermes's R&D?

Alkermes (ALKS) reported R&D of $103.35M in Q1 2026.

How has Alkermes's R&D changed year-over-year?

Alkermes's R&D increased by 43.9% year-over-year, from $71.82M to $103.35M.

What is the long-term trend for Alkermes's R&D?

Over 4 years (2021 to 2025), Alkermes's R&D has grown at a 1.3% compound annual growth rate (CAGR), from $308.15M to $323.96M.

Alkermes ALKS R&D

R&D at other companies

Bristol-Myers SquibbBMY

$2.65B+17.4%

Jazz PharmaceuticalsJAZZ

$196M+8.5%

Axsome TherapeuticsAXSM

$52.68M+17.6%

Ionis PharmaceuticalsIONS

$228.9M+1.6%

Neurocrine BiosciencesNBIX

$296.2M+12.5%

Arrowhead ResearchARWR

$173.25M+30.2%

Other financials

Income statement

See full

Revenue$392.9M+28.2%

Gross profit$331.3M+28.8%

Operating income-$48.3M-450%

Net income-$66.5M-396%

EPS (diluted)-$0.40-408%

Balance sheet

See full

Cash & equivalents$351.6M-12.1%

Total debt$1.6B+2,034%

Total equity$1.8B+15.9%

Total assets$4.3B+105%

Cash flow

See full

Operating cash flow-$165.7M-268%

CapEx$4.1M-59.5%

Free cash flow-$169.8M-291%

Valuation

See full

Market cap$7.5B+9.7%

Enterprise value$8.73B+41.2%

P/E49.1×+29.7×

P/S4.8×+0.3×

Profitability

See full

Gross margin86.6%+2.2pp

Operating margin12.3%-13.6pp

Net margin9.8%-13.5pp

FCF margin14.2%-17.6pp

Returns & leverage

See full

Return on equity9.4%-16.1pp

Debt / equity0.9×+0.9×

Current ratio2.3×-1.1×

Where this comes from

Reported directly by Alkermes in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Alkermes’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alkermes's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Alkermes's R&D?: Alkermes (ALKS) reported R&D of $103.35M in Q1 2026.
How has Alkermes's R&D changed year-over-year?: Alkermes's R&D increased by 43.9% year-over-year, from $71.82M to $103.35M.
What is the long-term trend for Alkermes's R&D?: Over 4 years (2021 to 2025), Alkermes's R&D has grown at a 1.3% compound annual growth rate (CAGR), from $308.15M to $323.96M.